Login / Signup

Current factor IX replacement options for hemophilia B and the challenges ahead.

Massimo FranchiniMarco ZaffanelloDaniele Focosi
Published in: Expert opinion on pharmacotherapy (2023)
The recent introduction of recombinant EHL FIX products has represented a major advance in the therapeutic management of hemophilia B patients, permitting both a reduction of treatment burden and improving patients' compliance to prophylaxis and, ultimately, quality of life.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • prognostic factors
  • risk factors
  • smoking cessation